Profluent signs $2.25B partnership with Eli Lilly for AI-designed gene editors
What’s the deal? Profluent has signed a multi-programme research collaboration with Eli LillyDealroom has a profile for this one. Try Dealroom → worth up to $2.25B. Lilly will have exclusive rights to develop and commercialise selected enzymes designed by Profluent’s AI platform.
Profluent receives an undisclosed upfront payment and research funding, with the potential for up to $2.25B in development and commercial milestone payments plus royalties on net sales. The deal marks Profluent’s first big pharma partnership.
Why now? The collaboration targets a problem current gene-editing tools cannot solve. CRISPR and its variants typically fix small DNA errors, but many genetic diseases — cystic fibrosis and GJB2-related hearing loss among them — involve hundreds of different mutations across patients. No single edit can address them all.
Profluent’s approach uses AI to design site-specific recombinases — enzymes capable of inserting entire kilobase-scale stretches of DNA at precise locations in the genome. Founded in 2022 by CEO Ali MadaniDealroom has a profile for this one. Try Dealroom →, the Emeryville, California-based company trains large language models on protein databases, then prompts them to design enzymes for specific disease targets. Head of gene editing Peter CameronDealroom has a profile for this one. Try Dealroom → described the challenge: “If you didn’t have AI, this would be utterly intractable.” The company first drew attention in 2024 when it published an AI model that designed novel Cas enzymes from scratch — a proof of concept inspired by research at Salesforce. Profluent raised $106M in November 2025, co-led by Altimeter Capital and Bezos Expeditions.
For Lilly, this is part of a broader bet on AI-driven drug discovery. The pharma struck a $2.75B deal with InSilico Medicine in March 2026 and has signed at least 15 AI-related deals in the past five years — more than any other drugmaker, according to Bloomberg Intelligence. Lilly has also partnered with Nvidia to build an AI supercomputer for drug discovery, and separately signed a $1.2B recombinase deal with Seamless TherapeuticsDealroom has a profile for this one. Try Dealroom → earlier in 2026 focused on hearing loss.
What could go wrong? No AI-designed drug has won US approval. Recombinase-based gene editing is even earlier-stage than CRISPR therapeutics, which took over a decade from discovery to the first approved treatment (Casgevy, December 2023). The deal discloses no target diseases, no programme count, and no upfront figure — so the $2.25B headline is entirely contingent on milestones that may never be reached.
Profluent has $149M in total funding and 60 employees. Delivering on a multi-programme collaboration with a $790B pharma partner will test the company’s operational capacity. And the competitive landscape is intensifying: Lilly alone has signed Kelonia Therapeutics, CrossBridge BioDealroom has a profile for this one. Try Dealroom →, and Ajax Therapeutics acquisitions in the past month.
The signal: Big pharma is pricing AI-designed biology at billions before a single clinical proof point. The Lilly–Profluent deal, the Lilly–InSilico deal, and similar pacts signal that the industry now treats AI protein design as a viable drug discovery modality, not a research curiosity.
What separates Profluent is the ambition to go beyond editing: designing entirely new enzymes that can rewrite entire passages of genetic code. If it works, the implications stretch well beyond Lilly’s pipeline — kilobase-scale insertion could open a universal approach to genetic diseases that today require mutation-by-mutation treatments.
Sources:
Reuters
Bloomberg
STAT News
BioSpace
Pharmaphorum
Image generated by AI
J.V.
